170,563 results match your criteria Metastatic Carcinoma


Metastatic insidious super giant basal cell carcinoma.

BMJ Case Rep 2022 Jun 27;15(6). Epub 2022 Jun 27.

Yale-Waterbury Internal Medicine Residency, Yale University School of Medicine, Waterbury, Connecticut, USA

A middle-aged woman presented with a mechanical fall. Physical examination revealed a massive purulent ulcerated lesion spanning her entire back and axilla, which had reportedly been brewing for over a decade. Punch biopsy revealed infiltrative basal cell carcinoma. Read More

View Article and Full-Text PDF

Surgical management in metastatic renal cell carcinoma.

Bull Cancer 2022 May;109(2S):2S59-2S65

Service de Chirurgie Oncologique 2, Institut Paoli-Calmettes, Marseille. Electronic address:

The management of metastatic renal cell carcinoma (mRCC) is evolving rapidly. In the era of antiangiogenic treatments, the Carmena trial showed no benefit of upfront cytoreductive nephrectomy compared to sunitinib alone for patients with intermediate or poor prognosis. The Surtime trial suggests that deferred nephrectomy after initiation of systemic therapy may be a better strategy. Read More

View Article and Full-Text PDF

Future treatment options in metastatic clear cell renal cell carcinoma.

Bull Cancer 2022 May;109(2S):2S47-2S58

Service d'Oncologie Médicale, Hôpital Européen Georges Pompidou, AP-HP. Centre - Université de Paris, Paris; INSERM, PARCC, Paris, France; Centre de Recherche des Cordeliers, INSERM, Université de Paris, Sorbonne Université, F-75006, Paris, France, Paris, France; Équipe labellisée Ligue contre le cancer. Electronic address:

The field of clear cell renal cell carcinoma (ccRCC) has undergone major changes in the last decade, both in terms of the understanding of the mechanisms of oncogenesis and the role of the tumor microenvironment in anti-tumor immunity, as well as in therapeutic developments. After the era of tyrosine kinase inhibitors (TKIs) targeting VEGFR and then the era of immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 pathway, we are now entering the era of combination therapy for first-line metastatic cancer (m-ccRCC), such as combinations including a TKI and a PD-1 inhibitor or combinations of PD-1 and CTLA-4 blockers. In this extremely dynamic environment, new molecules with various mechanisms of action will appear in the very near future: immune response modulators (other ICIs, pro-inflammatory cytokines, gut microbiota modulators), new anti-angiogenic agents (new TKIs, anti-HIF-1α antibodies), agents affecting cell metabolism (glutaminase inhibitors, tryptophan regulators or adenosine A2A receptor antagonists) or epigenetic regulators (HDAC inhibitors). Read More

View Article and Full-Text PDF

Clinical activity of immunotherapy-based combination first-line therapies for metastatic renal cell carcinoma: the right treatment for the right patient.

Bull Cancer 2022 May;109(2S):2S4-2S18

Medical Oncology Department, IMMUCARE, Centre Hospitalier Lyon Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), Pierre-Bénite, France.

Immunotherapy (IO) with checkpoint inhibitors with or without anti-angiogenic tyrosine kinase inhibitor (TKI)-based combinations have demonstrated superior efficacy over sunitinib for treatment-naive patients with metastatic clear-cell renal cell carcinoma (mRCC). Four of these combinations (nivolumab plus ipilimumab, pembrolizumab plus axitinib, nivolumab plus cabozantinib and pembrolizumab plus lenvatinib) represent new front-line standard-of-care options for mRCC patients, according to the International Metastatic RCC Database Consortium (IMDC) subgroups. Questions over the optimal treatment between IO-IO or IO-TKI combinations for mRCC patients in intermediate/poor IMDC risk groups and the optimal IO-TKI regimen for all IMDC risk groups remain unanswered. Read More

View Article and Full-Text PDF

Therapeutic sequencing in the era of first-line immune checkpoint inhibitor combinations, a novel challenge in patients with metastatic clear-cell renal cell carcinoma.

Bull Cancer 2022 May;109(2S):2S31-2S38

Department of Cancer Medicine, Gustave Roussy, Paris Saclay University, Villejuif, France.

Immune checkpoint inhibitor combinations have reshaped the treatment landscape of metastatic clear-cell renal cell carcinoma. As four regimens are now approved in the first-line setting, including nivolumab plus ipilimumab in intermediate and poor-risk patients, and pembrolizumab plus lenvatinib, nivolumab plus cabozantinib and pembrolizumab plus axitinib in all-comers, the choice of subsequent therapies is becoming a novel challenge for physicians. Such choices now rely on several compounds used as monotherapy which have demonstrated sustained activity after previous immune checkpoint or tyrosine kinase inhibitors. Read More

View Article and Full-Text PDF

Metastatic renal cell cancer and first-line combinations: for which patients? (focus on tolerance and health-related quality of life).

Bull Cancer 2022 May;109(2S):2S19-2S30

CHU Besançon, Oncologie, F-25030 Besançon cedex, France; INSERM, UMR1098, F-25020 Besançon cedex, France; Université de Franche-Comté, UBFC, F-25020 Besançon, France. Electronic address:

Until recently, the first-line treatments used in metastatic renal cell carcinoma were based on first-generation anti-VEGFR (vascular endothelial growth factor receptor) tyrosine kinase inhibitors (TKIs) as monotherapy. Trials combining immunotherapy (IO) (anti-CTLA4 + anti-PD-1) or immunotherapy with TKIs showed striking results in the first-line setting with improvement in overall response rates, progression-free survival and overall survival versus sunitinib. This allowed the combinations to gain registration in the US and Europe in the first-line advanced or metastatic clear-cell renal cell carcinoma setting. Read More

View Article and Full-Text PDF

Clinical outcomes of high-risk cutaneous squamous cell carcinomas treated with Mohs micrographic surgery alone: an analysis of local recurrence, regional nodal metastases, progression-free survival, and disease-specific death.

J Am Acad Dermatol 2022 Jun 24. Epub 2022 Jun 24.

Zitelli and Brodland Skin Cancer Center, Pittsburgh, PA 15232; University of Pittsburgh Medical Center, Pittsburgh, PA 15232.

Importance: The incidence of cutaneous squamous cell carcinomas (cSCC) continues to increase, and is now predicted that deaths from cSCC will surpass that of melanoma within the next 5 years. Although most cSCCs are successfully treated, there exists an important subset of high-risk tumors that have the highest propensity for local recurrence (LR), nodal metastasis (NM), and disease-specific death (DSD).

Objective: We investigated the clinical outcomes of high-risk cSCCs treated with MMS alone, analyzing LR, NM, DM, and DSD. Read More

View Article and Full-Text PDF

Genetic profile identification and clinicopathologic characteristics analysis of the thyroid-like low-grade nasopharyngeal papillary adenocarcinoma.

Pathol Res Pract 2022 Jun 16;236:153980. Epub 2022 Jun 16.

Department of Pathology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China. Electronic address:

Thyroid-like low-grade nasopharyngeal papillary adenocarcinoma (TL-LGNPPA) is an extremely rare malignancy bearing histomorphological similarities to papillary thyroid carcinoma with good prognosis. It's important to distinguish TL-LGNPPA from other papillary tumors including nasopharyngeal papillary adenocarcinoma (NPPA), metastatic and ectopic papillary thyroid cancer, and metastasized adenocarcinomas, etc. To date, only 48 cases of TL-LGNPPA have been reported in the English literatures. Read More

View Article and Full-Text PDF

ALK-fusion-positive secondary ameloblastic carcinoma reached complete response after using alectinib.

Oral Oncol 2022 Jun 24;132:105946. Epub 2022 Jun 24.

Department of Oral & Maxillofacial-Head & Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; College of Stomatology, Shanghai Jiao Tong University, Shanghai, China; Shanghai Key Laboratory of Stomatology, Shanghai, China; National Clinical Research Center for Oral Diseases, Shanghai, China; Shanghai Key Laboratory of Stomatology, Shanghai, China. Electronic address:

View Article and Full-Text PDF

Circ_0000523 regulates miR-1184/COL1A1/PI3K/Akt pathway to promote nasopharyngeal carcinoma progression.

Apoptosis 2022 Jun 27. Epub 2022 Jun 27.

Department of Otolaryngology Head and Neck Surgery, The Second Xiangya Hospital, Central South University, Renmin Middle Road No. 139, 410011, Changsha, Hunan Province, China.

Background: The present study is to investigate the biological functions and mechanisms of circular RNA_0000523 (circ_0000523) in nasopharyngeal carcinoma (NPC).

Methods: Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was conducted to examine the expression levels of circ_0000523 and microRNA-1184 (miR-1184) in NPC tissues and cells. Collagen type 1 alpha 1 chain (COL1A1) expression was assessed by qRT-PCR and immunohistochemistry (IHC) assay. Read More

View Article and Full-Text PDF

Radiotherapy for bone metastases of hepatocellular carcinoma: a hybrid systematic review with meta-analyses.

Int J Radiat Biol 2022 Jun 27:1-30. Epub 2022 Jun 27.

Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

Introduction: External beam radiation therapy (EBRT) is commonly used as a palliative treatment for bone metastases of hepatocellular carcinoma (HCC). We planned a hybrid systematic review that meta-analyzed the efficacy and feasibility of EBRT and reviewed the literature to answer specific clinical questions.

Methods: The PubMed, Medline, Embase, and Cochrane Library databases were searched through December 1, 2021. Read More

View Article and Full-Text PDF

A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear Cell Renal Cell Carcinoma.

Cancer Discov 2022 Jun 27. Epub 2022 Jun 27.

Memorial Sloan Kettering Cancer Center, New York, NY, United States.

It is poorly understood how the tumor immune microenvironment influences disease recurrence in localized clear cell renal cell carcinoma (ccRCC). Here we perform whole-transcriptomic profiling of 236 tumors from patients assigned to the placebo-only arm of a randomized, adjuvant clinical trial for high-risk localized ccRCC. Unbiased pathway analysis identifies myeloid-derived interleukin-6 (IL-6) as a key mediator. Read More

View Article and Full-Text PDF

Neuroendocrine Differentiation in the Setting of Prostatic Carcinoma: Contemporary Assessment of a Consecutive Series.

Histopathology 2022 Jun 27. Epub 2022 Jun 27.

Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Aim: Clinicopathologic characterization of contemporary series of neuroendocrine (NE) differentiation in the setting of prostatic carcinoma (PCa).

Methods & Results: We reviewed institutional databases for in-house cases with history of PCa and histopathologic evidence of NE differentiation during the disease course. 79 cases identified: 32 primary and 47 metastases. Read More

View Article and Full-Text PDF

Immune checkpoints in thymic epithelial tumors: challenges and opportunities.

Authors:
Nicolas Girard

Immunooncol Technol 2019 Oct 16;3:8-14. Epub 2019 Sep 16.

Head of the Thoracic Oncology Program, Institut du Thorax Curie-Montsouris, Institut Curie, Paris, France.

Thymic malignancies are rare mediastinal cancers, classified according to the World Health Organization's histopathologic classification which distinguishes thymomas from thymic carcinomas. One key consideration when discussing immunotherapy for thymic epithelial tumors is that one-third of patients diagnosed with thymomas present at the time of diagnosis with autoimmune disorders, the most common being myasthenia gravis. The first step in the understanding of autoimmunity in thymic epithelial tumors is to distinguish true autoimmune disorders from paraneoplastic syndromes; besides pathophysiology, clinical correlates, impact on oncological management and survival may differ strongly. Read More

View Article and Full-Text PDF
October 2019

Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First-Line Setting.

Front Oncol 2022 8;12:892156. Epub 2022 Jun 8.

University of Belgrade, Faculty of Medicine, Belgrade, Serbia.

Background: The emerging new standard of care for metastatic clear cell renal carcinoma (mRCC) becomes a challenge when access to new drugs is limited. In Serbia, sunitinib and pazopanib are the only available first-line therapies. The second-line treatment for mRCC has never been and is still not available. Read More

View Article and Full-Text PDF

Perineural Invasion Is a Significant Indicator of High Malignant Degree and Poor Prognosis in Esophageal Cancer: A Systematic Review and Meta-Analysis.

Front Oncol 2022 8;12:816270. Epub 2022 Jun 8.

Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.

Background: Perineural invasion (PNI) is a malignant metastatic mode of tumors and has been reported in many tumors including esophageal cancer (EC). However, the role of PNI in EC has been reported differently. This systematic review and meta-analysis aims to focus on the role of PNI in EC. Read More

View Article and Full-Text PDF

Plasma Circulating Tumor Epstein-Barr Virus for the Surveillance of Cancer Progression in Bone-Only Metastatic Nasopharyngeal Carcinoma.

Front Oncol 2022 10;12:860700. Epub 2022 Jun 10.

Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.

Background: Plasma Epstein-Barr virus DNA (EBV-DNA) is a sensitive and specific biomarker for nasopharyngeal carcinoma (NPC). We investigated whether longitudinal monitoring of EBV-DNA could accurately detect clinical disease progression in NPC patients with bone-only metastases.

Methods: In this retrospective study, a total of 105 patients with bone-only metastatic NPC who were treated with platinum-based first-line chemotherapy were enrolled. Read More

View Article and Full-Text PDF

Targeting ALK in Neuroendocrine Tumors of the Lung.

Front Oncol 2022 7;12:911294. Epub 2022 Jun 7.

Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland.

Background: () rearrangements are known oncogenic drivers in non-small cell lung cancer (NSCLC). Few case reports described the occurrence of such rearrangements in large cell neuroendocrine carcinomas (LCNECs) of the lung without information on clinical responses to ALK tyrosine kinase inhibitors (TKIs) in these cases. Currently, neuroendocrine tumors of the lungs are not screened for rearrangements. Read More

View Article and Full-Text PDF

Tubulocystic Renal Cell Carcinoma: An Underrecognized Clinicopathologic Entity.

Ochsner J 2022 ;22(2):182-187

Department of Urology, All India Institute of Medical Sciences, Jodhpur, India.

Tubulocystic renal cell carcinoma is a lesser-known neoplastic entity compared to other common histologic variants of renal cell carcinoma. The World Health Organization identified tubulocystic renal cell carcinoma as a newly recognized renal tumor in 2016. We report a case of tubulocystic renal cell carcinoma in a young adult. Read More

View Article and Full-Text PDF
January 2022

Targeted Cancer Therapies Causing Elevations in Serum Creatinine Through Tubular Secretion Inhibition: A Case Report and Review of the Literature.

Can J Kidney Health Dis 2022 21;9:20543581221106246. Epub 2022 Jun 21.

Division of Nephrology, Department of Medicine, McGill University Health Center, Montreal, QC, Canada.

Rationale: Targeted cancer therapies have revolutionized the field of oncology by selecting for specific molecular pathways, thus improving overall clinical prognosis. However, many of these targeted treatments have been reported to have adverse kidney effects, including acute kidney injury, interstitial nephritis, and glomerular disease. Furthermore, some of these targeted therapies have also been found to cause an asymptomatic rise in serum creatinine levels through inhibition of active tubular secretion. Read More

View Article and Full-Text PDF

Ramucirumab and Docetaxel in Patients with Metastatic Urothelial Carcinoma Harboring Fibroblast Growth Factor Receptor Alterations: A Case Series and Literature Review.

J Immunother Precis Oncol 2020 Feb 7;3(1):23-26. Epub 2020 Jan 7.

Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.

Metastatic urothelial carcinoma (mUC) has a poor prognosis with a 5-year survival probability of 4.8%. The mainstay of first-line treatment is platinum-based chemotherapy. Read More

View Article and Full-Text PDF
February 2020

A Case Report of a Cutaneous Mucinous Reaction Associated with Erlotinib Therapy Used in the Treatment of Metastatic Tonsillar Sinus Squamous Cell Carcinoma.

J Immunother Precis Oncol 2020 Feb 13;3(1):31-33. Epub 2019 Dec 13.

Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Cutaneous mucinoses are a diverse group of diseases that are occasionally seen in the context of an adverse drug reaction. We report the case of a 59-year-old male who presented with an asymptomatic, acneiform rash on his forehead, scalp, nose, upper chest, and upper back that had developed after treatment with erlotinib therapy used in the treatment of metastatic tonsillar sinus squamous cell carcinoma. Biopsy of these lesions demonstrated atypical histology that had features of both follicular mucinosis and myxedema. Read More

View Article and Full-Text PDF
February 2020

Primary Vaginal Adenocarcinoma of Intestinal-Type: A Case Report of a Rare Tumor With Review of Histology, Differential Diagnosis, and Literature.

Cureus 2022 May 24;14(5):e25298. Epub 2022 May 24.

Pathology and Laboratory Medicine, Creighton University School of Medicine, Omaha, USA.

Intestinal-type adenocarcinoma is a rare primary vaginal carcinoma. Vaginal adenocarcinomas are most frequently a metastatic lesion, and less commonly, have clear cell histology and occur in young women with diethylstilbestrol (DES) exposure in utero. Due to the limited diagnostic power of immunohistochemistry (IHC) in differentiating primary from metastatic adenocarcinoma of the vagina, clinical and radiological correlation is critical in this scenario. Read More

View Article and Full-Text PDF

Clinical Problem Solving: A 56-Year-Old Woman With Right Facial Weakness, Numbness, and Diplopia.

Neurohospitalist 2022 Jul 23;12(3):512-515. Epub 2022 Feb 23.

Neurology Department, Brigham and Women's Hospital, Boston, MA, USA.

We discuss a case of a middle-aged woman with a history of urothelial carcinoma, who presented with subacute progression of double vision, right facial numbness, and back pain. Her MRI brain and spine demonstrated multifocal enhancing lesions at the skull base and throughout the spine. Since her initial serum and cerebrospinal fluid (CSF) studies were unrevealing, she underwent a biopsy of her skull base lesion, which was initially concerning for infection. Read More

View Article and Full-Text PDF

Tumour mutational burden: primary versus metastatic tissue creates systematic bias.

Immunooncol Technol 2019 Dec 16;4:8-14. Epub 2019 Dec 16.

Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.

Tumour mutational burden (TMB) has emerged as a reproducible biomarker to predict immunotherapy response across multiple cancer types. However, a key aspect of TMB measurement that is often overlooked is the source of tissue sample used, which creates a potential for systematic bias. The predominant source is either primary or metastatic tumour tissue. Read More

View Article and Full-Text PDF
December 2019

Driving innovation for rare skin cancers: utilizing common tumours and machine learning to predict immune checkpoint inhibitor response.

Immunooncol Technol 2019 Dec 27;4:1-7. Epub 2019 Nov 27.

Department of Medical Oncology, University Medical Centre Groningen, the Netherlands.

Metastatic Merkel cell carcinoma (MCC) and cutaneous squamous cell carcinoma (cSCC) are rare and both show impressive responses to immune checkpoint inhibitor treatment. However, at least 40% of patients do not respond to these expensive and potentially toxic drugs. Development of predictive biomarkers of response and rational, effective combination treatment strategies in these rare, often frail patient populations is challenging. Read More

View Article and Full-Text PDF
December 2019

Metastasis to the Bladder: A Rare Site of Recurrence of Renal Cell Carcinoma.

Case Rep Urol 2022 17;2022:4339270. Epub 2022 Jun 17.

The James Buchanan Brady Urologic Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Renal cell carcinoma (RCC) is considered to be the deadliest urologic cancer with high rates of metastasis and recurrence after nephrectomy. RCC can metastasize to nearly any organ but most commonly metastasizes to the liver, lung, brain, and bone. To date, there are only about 40 reported cases of RCC with solitary bladder metastasis. Read More

View Article and Full-Text PDF

The natural history of low-risk non-muscle-invasive bladder cancer: a collaborative multi-centre study.

Int Urol Nephrol 2022 Jun 27. Epub 2022 Jun 27.

Leeds Teaching Hospitals NHS Trust, Leeds, UK.

Background: International guidelines vary in terms of their definition and recommendation for management of low-risk non-muscle-invasive bladder cancer (LRNMIBC). The ideal management for this large subset of bladder cancer patient remains unclear.

Objective: To evaluate long-term outcomes of patients with LRNMIBC. Read More

View Article and Full-Text PDF

Inhibition of HSP 90 is associated with potent anti-tumor activity in Papillary Renal Cell Carcinoma.

J Exp Clin Cancer Res 2022 Jun 27;41(1):208. Epub 2022 Jun 27.

Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.

Background: There is no universally accepted treatment for patients with advanced papillary renal cell carcinoma (PRCC). The presence of activating mutations in MET, as well as gain of chromosome 7, where the MET gene is located, are the most common genetic alterations associated with PRCC, leading to the clinical evaluation of MET tyrosine kinase inhibitors (TKIs) in this cancer. However, TKIs targeting MET selectively, as well as multitargeted TKIs with activity against MET demonstrate modest efficacy in PRCC and primary and secondary treatment failure is common; other approaches are urgently needed to improve outcomes in these patients. Read More

View Article and Full-Text PDF